Organisation paid for research Program year 2025 Source: CMS Open Payments

Asclepes Research Centers

Neither a doctor nor a teaching hospital

Research payments

$396,519

114 payments

Through program year 2025, Asclepes Research Centers is reported as receiving $396,519 in research payments, across 114 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$22,953	9
2024	Research	$738	1
2023	Research	$116,840	7
2022	Research	$87,758	11
2021	Research	$55,365	29
2020	Research	$43,028	25
2019	Research	$69,836	32

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $233,055 12 payments
Incyte Corporation $67,456 30 payments
GlaxoSmithKline, LLC. $19,055 5 payments
Pfizer Inc. $17,228 9 payments
AbbVie, Inc. $16,840 10 payments
Boehringer Ingelheim International GmbH $15,177 42 payments
E.R. Squibb & Sons, L.L.C. $8,472 1 payment
Celgene Corporation $7,324 2 payments
Biohaven Pharmaceutical Holding Company Ltd. $5,000 1 payment
Supernus Pharmaceuticals, Inc. $3,492 1 payment

Studies the money was for Research payments · program years 2019–2025

Connex 2 $124,117 4 payments
A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor, CITADEL 204 $56,203 16 payments
BI 425809 Adjunctive Computerized Cognitive Traini $51,624 6 payments
Connex X $31,040 2 payments
Proof of Concept and DRF with TRPC4 5 inhibitor in $26,415 1 payment
An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 2Arm Study to Investigate A Repeat 5Day Course of Nirmatrelvirritonavir Compared to Placeboritonavir in Participants at Least 12 Years of Age With Rebound of Covid19 Symptoms and Rapid Antigen Test Positivity $15,657 5 payments
Study name not reported $15,150 3 payments
BI 425809 Adjunctive Computerized Cognitive Training (CCT) $15,037 41 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma $9,375 1 payment
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $8,472 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.